Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer | Oncotarget
Pertuzumab: Uses, Interactions, Mechanism of Action | DrugBank Online
Trastuzumab — Mechanism of Action and Use in Clinical Practice | NEJM
Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond: Trends in Cancer
How PERJETA® (pertuzumab) works for HER2+ Breast Cancer | HCP
Figure 1 | Recent Developments in HER2-Directed Therapy in Breast Cancer | SpringerLink
Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer | British Journal of Cancer
Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes - ScienceDirect
Cancers | Free Full-Text | Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer | Journal for ImmunoTherapy of Cancer
Pertuzumab is a fully humanized monoclonal antibody based on the human... | Download Scientific Diagram
Mode action of current ErbB2 inhibitors. Trastuzumab, pertuzumab, and... | Download Scientific Diagram
Targeted therapeutic options and future perspectives for HER2-positive breast cancer | Signal Transduction and Targeted Therapy
Pertuzumab: Development Beyond Breast Cancer | Anticancer Research
How PERJETA® (pertuzumab) works for HER2+ Breast Cancer | HCP
Pertuzumab in HER2-positive early breast cancer: current use and perspectives | Future Oncology
Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silicobased mechanism | Breast Cancer Research | Full Text
Precision medicine and personalized breast cancer: combination pertuzu | PGPM
Cancers | Free Full-Text | Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer
References in Evolving novel anti-HER2 strategies - The Lancet Oncology
Cancers | Free Full-Text | The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer | HTML
Anti-HER2 therapy in metastatic breast cancer: many choices and future directions | SpringerLink
HER2-targeted therapies — a role beyond breast cancer | Nature Reviews Clinical Oncology
Dual HER2 blockade with trastuzumab and pertuzumab in HER2-amplified... | Download Scientific Diagram
Pertuzumab in human epidermal growth-factor receptor 2-positive breast | IJWH
Toxicology of Trastuzumab: An Insight into Mechanisms of Cardiotoxicity | Bentham Science
Proposed Mechanism of Action | PHESGO® (pertuzumab / trastuzumab / hyaluronidase-zzfx)
